LabMol - Laboratory for Molecular Modeling and Drug Design, Faculdade de Farmacia, Universidade Federal de Goias - UFG, Goiânia, GO 74605-170, Brazil.
Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ 21040-900, Brazil; Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, UK.
Drug Discov Today. 2018 Nov;23(11):1833-1847. doi: 10.1016/j.drudis.2018.06.014. Epub 2018 Jun 20.
Despite the recent outbreak of Zika virus (ZIKV), there are still no approved treatments, and early-stage compounds are probably many years away from approval. A comprehensive A-Z review of the recent advances in ZIKV drug discovery efforts is presented, highlighting drug repositioning and computationally guided compounds, including discovered viral and host cell inhibitors. Promising ZIKV molecular targets are also described and discussed, as well as targets belonging to the host cell, as new opportunities for ZIKV drug discovery. All this knowledge is not only crucial to advancing the fight against the Zika virus and other flaviviruses but also helps us prepare for the next emerging virus outbreak to which we will have to respond.
尽管寨卡病毒（ZIKV）最近爆发，但目前仍没有批准的治疗方法，早期的化合物可能还需要数年时间才能获得批准。本文全面综述了寨卡病毒药物发现研究的最新进展，重点介绍了药物再利用和计算指导的化合物，包括已发现的病毒和宿主细胞抑制剂。还描述和讨论了有前景的寨卡病毒分子靶标以及宿主细胞靶标，这为寨卡病毒药物发现提供了新的机会。所有这些知识不仅对推进对抗寨卡病毒和其他黄病毒的斗争至关重要，还有助于我们为下一次我们必须应对的新兴病毒爆发做好准备。
